18838885

Source:http://linkedlifedata.com/resource/pubmed/id/18838885

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0146224, umls-concept:C0153467, umls-concept:C0205065, umls-concept:C0279284, umls-concept:C0442027, umls-concept:C0920321, umls-concept:C1522690
pubmed:issue	5
pubmed:dateCreated	2008-10-7
pubmed:abstractText	The feasibility, safety, and preliminary efficacy of a second-line combination therapy for oral topotecan and pegylated liposomal doxorubicin in patients with platinum-resistant or refractory epithelial ovarian, peritoneal, or tubal carcinoma were investigated in this phase I trial.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8207754
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Topotecan, http://linkedlifedata.com/resource/pubmed/chemical/pegylated liposomal doxorubicin
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1537-453X
pubmed:author	pubmed-author:FuscoNancyN, pubmed-author:HabaPamP, pubmed-author:RodriguezMichaelM, pubmed-author:RosePeter GPG, pubmed-author:SmrekarMaryM
pubmed:issnType	Electronic
pubmed:volume	31
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	476-80
pubmed:meshHeading	pubmed-meshheading:18838885-Adenocarcinoma, Clear Cell, pubmed-meshheading:18838885-Administration, Oral, pubmed-meshheading:18838885-Adult, pubmed-meshheading:18838885-Aged, pubmed-meshheading:18838885-Aged, 80 and over, pubmed-meshheading:18838885-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18838885-Carcinoma, Endometrioid, pubmed-meshheading:18838885-Cystadenocarcinoma, Serous, pubmed-meshheading:18838885-Doxorubicin, pubmed-meshheading:18838885-Drug Resistance, Neoplasm, pubmed-meshheading:18838885-Fallopian Tube Neoplasms, pubmed-meshheading:18838885-Feasibility Studies, pubmed-meshheading:18838885-Female, pubmed-meshheading:18838885-Humans, pubmed-meshheading:18838885-Maximum Tolerated Dose, pubmed-meshheading:18838885-Middle Aged, pubmed-meshheading:18838885-Organoplatinum Compounds, pubmed-meshheading:18838885-Ovarian Neoplasms, pubmed-meshheading:18838885-Peritoneal Neoplasms, pubmed-meshheading:18838885-Polyethylene Glycols, pubmed-meshheading:18838885-Prognosis, pubmed-meshheading:18838885-Survival Rate, pubmed-meshheading:18838885-Topotecan
pubmed:year	2008
pubmed:articleTitle	A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
pubmed:affiliation	Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation/Case Western Reserve University, Cleveland, OH 44195, USA. rosep@ccf.org
pubmed:publicationType	Journal Article, Clinical Trial, Phase I